Journal of Clinical Oncology
Articles in this Issue
Integrating tumor mutation profiles, preoperative circulating tumor DNA (ctDNA), and clinical features to a predicting model for early peritoneal recurrence in stage II-III gastric cancer following curative gastrectomy.
3056 Background: Peritoneal recurrence is the common failure pattern after curative gastrectomy and is most consequential...
Concurrent chemoradiotherapy plus cytokine-induced killer cells therapy or observation in patients with locoregionally advanced nasopharyngeal carcinoma: A ten-year follow-up of a randomized, phase II study.
2558 Background: Concurrent chemoradiotherapy (CCRT) is the standard of care for patients with locoregionally advanced nas...
Clinical diagnostic utility of cerebrospinal fluid ctDNA in central nervous system lymphoma: A systematic review and meta-analysis.
e15067 Background: Diagnosis of central nervous system lymphoma (CNSL), including primary (PCNSL) and secondary (SCNSL) fo...
A real-world analysis on the management of post-mastectomy lymphedema in breast cancer patients: The therapeutic promise of glucagon-like peptide-1 receptor agonist.
e12695 Background: Post mastectomy lymphedema syndrome (PMLS) is an established complication of mastectomy, and the risk i...
Next-generation sequencing in non-small cell lung cancer management in Lebanon: Clinical practices and barriers to implementation.
e20692 Background: Next-generation sequencing (NGS) is a cornerstone of precision oncology; it enables comprehensive genom...
Comparative outcomes of prophylactic anticoagulation in patients with multiple myeloma receiving immunomodulatory therapy.
e19542 Background: Patients with multiple myeloma have a substantially increased risk of venous thromboembolism (VTE), fur...
Prospective comparison of patient-derived organoid drug screening with standard guideline recommendations for colorectal cancer liver metastasis.
e15609 Background: Treatment options for colorectal cancer liver metastasis (CRLM) are limited, and resistance to standard...
Survival outcomes and prognostic factors in luminal A (LumA) early breast cancer (EBC): Real-world evidence from a public cancer center in Peru.
e23406 Background: Luminal A (LumA) early breast cancer (EBC) generally has excellent prognosis (5-year survival ≥ 95%) du...
Circulating tumor DNA–based clinical-genetic (CG) prognostic model for radiographic progression-free survival (rPFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Analysis of Alliance A031201.
5018 Background: mCRPC is characterized by marked molecular heterogeneity and variable clinical outcomes. Circulating tumo...
Impact of market entry of biosimilars in the US on cancer biologics' pricing strategies, market share, and payer costs.
11073 Background: Biosimilars have been anticipated to lower the financial burden of cancer for payors as well as patients...
Phase Ia study of VRN101099, a brain-penetrant, highly selective covalent HER2 inhibitor, in HER2-positive or HER2-mutant advanced solid tumors.
1048 Background: Despite advances in HER2-targeted therapies, including trastuzumab deruxtecan (T-DXd), unmet needs remain...
The TIGeR-PaC phase 3 clinical trial examining intra-arterial gemcitabine versus intravenous gemcitabine: Pharmacokinetic and pharmacodynamic sub-study.
e16463 Background: Intra-arterial delivery of gemcitabine (IAG) targeted to tumors/tissue may provide higher local drug po...
Survival outcomes comparing sequencing of CAR-T followed by BiTE versus BiTE followed by CAR-T in patients with relapsed multiple myeloma.
7511 Background: Chimeric antigen receptor T-cell (CAR-T) therapies and bispecific T-cell engager (BiTE) antibodies for re...
First-line immunotherapy strategies in pMMR advanced endometrial cancer: A network meta-analysis.
e17650 Background: Optimal first-line treatment for mismatch repair–proficient (pMMR) advanced or recurrent endometrial ca...
Artificial intelligence–enabled analysis of prognostic PI3K pathway alterations in African American colorectal cancer patients treated with FOLFOX.
e15511 Background: The phosphoinositide 3-kinase (PI3K) signaling pathway regulates tumor growth, metabolism, and treatmen...
Pre-diagnostic imaging and radiology report–based risk modeling for pancreatic ductal adenocarcinoma.
e16017 Background: Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer and remains one of...
Rethinking cancer attribution in oncology VBC models: E&M vs treatment-based approach.
1580 Background: Patients with multiple cancers are uncommon. In value-based care models such as EOM (Enhancing Oncology M...
Use of visual analogue scale (VAS) and analgesia administration in oncology inpatients: An audit from a tertiary care centre.
e24061 Background: Effective pain assessment and timely administration of analgesia are essential components of quality ca...
Activity of NP-G2-044 (fascin inhibitor) + anti–PD-1 in ICI-resistant advanced/metastatic solid tumors with expansion in cutaneous squamous cell carcinoma (CSCC).
e21557 Background: Most patients do not respond to anti–PD-1 therapy, and many responders develop acquired resistance. In...
Neoadjuvant atirmociclib plus letrozole versus letrozole alone in HR+/HER2− breast cancer: Results from FourLight-2, a randomized phase 2 window of opportunity study.
518 Background: In the neoadjuvant setting, endocrine therapy is a standard of care option in patients (pts) with HR+ brea...
Treatment strategies in metastatic NSCLC after progression to immuno-chemotherapy: A random-effects network meta-analysis of phase III trials.
e20509 Background: Patients with metastatic non-small cell lung cancer (mNSCLC) progressing after immunotherapy (IO) plus...
Early-onset <i>BRAF</i> -mutant metastatic colorectal cancer: A distinct clinical and molecular signature.
e15533 Background: BRAF V600E–mutant metastatic colorectal cancer (mCRC) is associated with poor prognosis and marked biol...
Targeted long-acting cisplatin–SRGel for enhanced chemoradiation in head and neck cancer: Preclinical pharmacokinetics, safety, and efficacy.
e18077 Background: Systemic cisplatin combined with radiotherapy is the standard of care for unresectable head and neck sq...
Non-melanoma skin cancer–related mortality in the United States: A 25-year CDC WONDER analysis.
9580 Background: Non-melanoma skin cancer (NMSC), including basal cell and squamous cell carcinoma, is the most common mal...
Association between ctDNA kinetics and overall survival in patients with urothelial cancer.
e16574 Background: Circulating tumor DNA (ctDNA) dynamics have emerged as a promising biomarker of prognosis and therapeut...